• If you attended the Annual Meeting of the American Society for Hematology (ASH) last December, then you might have noticed some exciting clinical-trial news about the treatment of multiple myeloma, especially for patients that have relapsed and/or are refractory to chemotherapies such as bortezomib. (cancertherapyadvisor.com)
  • Vorinostat, an oral histone deacetylase (HDAC) inhibitor manufactured by Merck that was previously approved by the Food and Drug Administration for the treatment of cutaneous T-cell lymphoma, has shown promising activity in patients with relapsed and/or refractory multiple myeloma and is currently in Phase 3 trials for this disease. (cancertherapyadvisor.com)
  • One oral presentation (Abstract No. 813) was titled "Final Results from the Bortezomib-Naive Group of PX-171-004, a Phase 2 Study of Single-Agent Carfilzomib in Patients with Relapsed and/or Refractory Multiple Myeloma. (cancertherapyadvisor.com)
  • Combination therapies involving melphalan, a small-molecule DNA alkylating agent, are commonly prescribed to patients with relapsed or refractory MM, necessitating the stratification of responding patients to minimize toxicities and improve quality of life. (snmjournals.org)
  • In explaining the rationale for the study, Parekh and colleagues noted that while the use of BCMA-directed CAR T-cell therapies in relapsed and refractory multiple myeloma have demonstrated high response rates, optimal treatment regimens have yet to be defined for patients who relapse. (medpagetoday.com)
  • They had received a median of five previous treatment lines (including autologous stem cell transplant in 94.9% of patients), and most (83.5%) were triple class-refractory (refractory to ≥1 immunomodulatory drug, ≥1 proteasome inhibitor, and ≥1 anti-CD38 monoclonal antibody). (medpagetoday.com)
  • Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy. (bvsalud.org)
  • The adoptive transfer of CAR - T cells , which are modified T cells expressing chimeric antigen receptors ( CARs ), to target B cell maturation antigen (BCMA) has demonstrated impressive results in treating relapsed/refractory multiple myeloma . (bvsalud.org)
  • To the best of our knowledge , this is the first report of the successful treatment of ITP that arose in a relapsed/refractory multiple myeloma patient following anti-BCMA CAR - T cell infusion. (bvsalud.org)
  • Chimeric antigen receptor (CAR) T-cell therapy is an example of how immunotherapy is revolutionizing the treatment of hematologic malignancies with unprecedented response rates in patients with relapsed/refractory lymphoma, multiple myeloma, and acute lymphoblastic leukemia. (ajmc.com)
  • Research Objective We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment Impact Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production. (ca.gov)
  • In a phase III trial published in the journal Lancet Oncology on September 18, 2014, researchers San-Miguel et al investigated the potential of combination therapy with panobinostat, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma. (pharmacytimes.com)
  • In a press release, lead author of the 215-site clinical trial Jesus San-Miguel, MD, stated, "The PANORAMA-1 study is the first Phase III trial to show the superiority of LBH589 plus bortezomib and dexamethasone over one of the standard two-drug regimens for patients with relapsing and/or refractory multiple myeloma. (pharmacytimes.com)
  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. (pharmacytimes.com)
  • The advent of successful monoclonal antibody therapy in the treatment of relapsed/refractory myeloma has dramatically improved the prognosis of patients for whom currently approved novel therapies have failed. (ascopost.com)
  • The premise for the use of daratumumab in this setting was built around the construct that multiple myeloma cells uniformly overexpress CD38, and that as a CD38-targeting human immunoglobulin G (IgG1) kappa monoclonal antibody, this agent would be active in refractory patients. (ascopost.com)
  • Given that daratumumab may have a role in immune modulation by means of depletion of CD38-positive regulator immune suppressor cells, which leads to a greater clonal expansion of T cells in patients who respond, a phase I/II study of daratumumab, lenalidomide, and dexamethasone in patients with relapsed and refractory multiple myeloma was performed. (ascopost.com)
  • Some patients also become refractory, which means they stop responding to treatment and still have myeloma cells in their bone marrow. (novartis.com)
  • 3 Approximately 75,000 patients around the world are living with relapsed or refractory multiple myeloma. (novartis.com)
  • Cilta-cel is an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR)-T cell therapy for the treatment of adults with relapsed or refractory multiple myeloma who have received at least three prior therapies, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 antibody. (pharmiweb.com)
  • The submission is based on results from the Phase 1b/2 CARTITUDE-1 study conducted in the US and Japan, which evaluated the efficacy and safety of cilta-cel for patients with relapsed or refractory multiple myeloma. (pharmiweb.com)
  • We look forward to closely collaborating with our partner Janssen and the MHLW in order to make cilta-cel available to patients living with relapsed or refractory multiple myeloma, who have exhausted several standard-of-care treatments and are facing poor prognoses. (pharmiweb.com)
  • Cilta-cel is an investigational chimeric antigen receptor T cell (CAR-T) therapy, formerly identified as JNJ-4528 in the U.S. and Europe and LCAR-B38M CAR-T cells in China, that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and in earlier lines of treatment. (pharmiweb.com)
  • 4 Relapsed myeloma is when the disease has returned after a period of initial, partial or complete remission and does not meet the definition of being refractory. (pharmiweb.com)
  • 5 Refractory multiple myeloma is when a patient's disease is non-responsive or progresses within 60 days of their last therapy. (pharmiweb.com)
  • The Food and Drug Administration granted accelerated approval for Elrexfio for the treatment of patients with relapsed or refractory multiple myeloma who previously received at least four lines of therapy. (curetoday.com)
  • The Food and Drug Administration (FDA) approved Elrexfio (elranatamab-bcmm) to treat adults with relapsed or refractory multiple myeloma who previously received four or more lines of therapy. (curetoday.com)
  • This FDA approval was based on findings from the phase 2 MagnetisMM-3 trial, which assessed the efficacy of Elrexfio in 123 patients with heavily pretreated relapsed or refractory multiple myeloma. (curetoday.com)
  • In palliative care, patients receiving corticosteroids for symptoms such as fatigue, anorexia, refractory nausea and vomiting or adjuvant analgesia and symptomatic treatment of cord compression or raised intracranial pressure, Dexamethasone phosphate/DEMO may be administered subcutaneously (see section 4.2) as an alternative to the oral route when the latter is unacceptable or no longer feasible. (who.int)
  • NICE is unable to make a recommendation on teclistamab (Tecvayli) for treating relapsed or refractory multiple myeloma after 3 or more therapies in adults. (bvsalud.org)
  • Takeda is also presenting key insights from the US MM-6 trial, which investigates the effectiveness and safety of an in- class transition to oral NINLARO in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who have previously received a parenteral bortezomib-based triplet induction therapy. (takeda.com)
  • Two new treatments-elranatamab (Elrexfio™) and talquetamab (Talvey™) were approved by the U.S. Food and Drug Administration in August 2023 to complement three existing therapies approved in the last two years. (tgen.org)
  • Managed care professionals should have an understanding of the clinical trial data and place in therapy in lymphoma, myeloma, and acute lymphoblastic leukemia as well as guideline recommendations for adverse effect management associated with CAR T-cell therapies. (ajmc.com)
  • Multiple myeloma (MM) represents 1% of all cancers and is the second most common hematologic malignancy, after lymphoma. (scielo.br)
  • For treatment of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma. (aetna.com)
  • CD19-directed CAR T therapy is now approved to treat a range of B-cell malignancies including childhood B cell acute lymphoblastic leukemia and adult large B cell lymphoma, primary mediastinal large B cell lymphoma, mantle cell lymphoma and follicular lymphoma. (lls.org)
  • Effectiveness of CAR-T therapies in the general population of lymphoma patients may differ from effectiveness demonstrated in trials. (rand.org)
  • However, no biomarkers have been clinically validated that can identify patients most likely to respond to this treatment," said study lead Robert Orlowski, M.D., Ph.D., chair ad interim of Lymphoma/Myeloma . (mdanderson.org)
  • The purpose of this study is to find the highest dose of the investigational drug CFT7455 that can be given safely in people with non-Hodgkin lymphoma (NHL) or multiple myeloma that has come back or continued to grow despite treatment. (mskcc.org)
  • CAR (chimeric antigen receptor) T-cell therapy is the latest wave in hematology and has been validated in various forms of leukemia and lymphoma . (medscape.com)
  • Design and Methods Oral cyclophosphamide, thalidomide, and dexamethasone was compared with infusional cyclophosphamide, vincristine, doxorubicin, and dexamethasone in patients with newly diagnosed multiple myeloma. (haematologica.org)
  • Combination vincristine, doxorubicin, and dexamethasone (VAD) is considered a standard infusional induction therapy for younger MM patients prior to HDT and ASCT. (haematologica.org)
  • CHICAGO and RARITAN, NJ, June 4, 2017 - Janssen Research & Development, LLC today announced new data from updated analyses of the pivotal Phase 3 CASTOR and POLLUX clinical studies, demonstrating that DARZALEX ® (daratumumab) in combination with bortezomib and dexamethasone, or lenalidomide and dexamethasone, improved progression-free survival (PFS) and the overall response rate (ORR) for previously-treated patients with multiple myeloma, regardless of cytogenetic risk. (jnj.com)
  • Additionally, data from the Phase 1b MMY1001 study will show the potential of daratumumab in combination with carfilzomib, lenalidomide and dexamethasone (KRd) for newly diagnosed patients with multiple myeloma. (jnj.com)
  • Adding panobinostat to a combination treatment of bortezomib and dexamethasone in heavily pretreated patients boosts progression-free survival, but overall survival data are not yet mature. (pharmacytimes.com)
  • Researchers found that adding carfilzomib to standard treatment (lenalidomide and dexamethasone) resulted in 8.7 months of longer remission, almost 50 percent longer than the standard two-drug combination (26.3 months versus 17.6 months). (sciencedaily.com)
  • Taken together, these outstanding results led to U.S. Food and Drug Administration (FDA) approval for daratumumab in combination with both lenalidomide and dexamethasone and with bortezomib (Velcade) and dexamethasone for the treatment of patients who have received at least one prior therapy. (ascopost.com)
  • Moreover, after continued treatment, responses deepened, with a rate of complete response that was twice as high with daratumumab-based therapy compared with lenalidomide and dexamethasone alone in the POLLUX trial and similarly favorable results in the CASTOR trial. (ascopost.com)
  • Some participants with multiple myeloma will receive CFT7455 in combination with dexamethasone. (mskcc.org)
  • The safety and efficacy of oral pomalidomide was evaluated in a phase 2 study, in combination with low-dose dexamethasone, a corticosteroid used in standard treatment of multiple myeloma. (oncologynurseadvisor.com)
  • Overall, 21 (19%) of the patients receiving pomalidomide and dexamethasone died during the study, most commonly due to progressive multiple myeloma. (oncologynurseadvisor.com)
  • Consolidation treatment with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRD) followed by maintenance with lenalidomide improved progression-free survival (PFS) and the depth of response compared with maintenance alone in transplant-eligible patients with newly diagnosed multiple myeloma, researchers found. (medpagetoday.com)
  • In this study, patients received induction with 3 to 4 cycles of vincristine, cyclophosphamide, and dexamethasone, and mobilization of stem cells was performed, after which patients either underwent therapy with 4 cycles of VMP, or high-dose melphalan and single or double ASCT. (medpagetoday.com)
  • Dexamethasone phosphate/DEMO is recommended for systemic administration by intravenous or intramuscular injection when oral therapy is not feasible or desirable in the following conditions. (who.int)
  • Dexamethasone has been shown to be beneficial when used in the early treatment of shock, but it may not influence overall survival. (who.int)
  • Dexamethasone phosphate/DEMO is indicated in the treatment of coronavirus disease 2019 (COVID-19) in adult and adolescent patients (aged 12 years and older with body weight at least 40 kg) who require supplemental oxygen therapy. (who.int)
  • A large Italian study demonstrated the feasibility of using carfilzomib in frontline therapy combined with either cyclophosphamide - dexamethasone (KCD) or lenalidomide -dexamethasone (KRD). (medscape.com)
  • Background Thalidomide is active in multiple myeloma and is associated with minimal myelosuppression, making it a good candidate for induction therapy prior to high-dose therapy with autologous stem-cell transplantation. (haematologica.org)
  • High-dose therapy (HDT) combined with autologous stem-cell transplantation (ASCT) provides superior response and survival outcomes versus standard chemotherapy in patients with newly diagnosed (ND) multiple myeloma (MM). 1 , 2 Standard induction chemotherapy regimens, however, are often associated with hematologic stem-cell toxicity, which may compromise the collection of stem cells for ASCT. (haematologica.org)
  • Legend Biotech said in an SEC filing that it has terminated a Phase 1 trial of its autologous CAR T therapy LB1901 due to a lack of clinical benefit demonstrated by a different product candidate expressing the same CAR protein. (ppf.eu)
  • In the last decade, the availability of autologous stem cell transplantation and combination therapies consisting of immunomodulatory drugs, proteasome inhibitors, and other chemotherapeutics has improved median 5-y survival from 34.6% in 2004 to 49.6% in 2013 ( 3 , 4 ). (snmjournals.org)
  • CAR T-cells may be manufactured either from the patient's own blood, known as an autologous treatment, or from the blood of a healthy donor, known as an allogeneic treatment. (wikipedia.org)
  • Translational Candidate A single-chain bispecific chimeric antigen receptor (CAR) targeting BCMA and CS1 will be used to in autologous T-cell therapy for multiple myeloma. (ca.gov)
  • Translational Candidate Lenti/iNKT-sr39TK Modified Autologous Human CD34+ Hematopoietic Stem Cells (HSCs) Area of Impact The targeted area of impact for the candidate is cancer therapy, in particular cancers that are lacking existing effective treatments. (ca.gov)
  • Although multiple myeloma patients younger than 66 years of age have an aggressive presentation, this did not translate into an inferior overall survival, particularly in those undergoing autologous hematopoietic stem cell transplantation. (scielo.br)
  • Of these, 27.91% had a main diagnosis indicating the transplantation of Multiple Myeloma (MM), and 58.14 received autologous transplantation. (bvsalud.org)
  • MM is considered relative paucity of CNS invasion by MM an incurable disease despite various meth- in comparison with other tumours, whether ods of treatment, including autologous bone solid or haematological, remain unknown, marrow transplantation [ 3 ]. (who.int)
  • The Phase 3 trial compares several outcome measures and the safety profile of vorinostat alone or in combination with bortezomib in 637 participants with progressive multiple myeloma and was presented by Merck as Abstract No. 811 at ASH. (cancertherapyadvisor.com)
  • Targeted therapy include proteasome inhibitors such as bortezomib (Velcade) and carfilzomib (Kyprolis), and "immunomodulatory agents" such as lenalidomide (Revlimid) and pomalidomide (Pomalyst). (dukehealth.org)
  • A gene known as TJP1 (tight junction protein 1) could help determine which multiple myeloma patients would best benefit from proteasome inhibitors such as bortezomib, as well as combination approaches to enhance proteasome inhibitor sensitivity, according to a study led by The University of Texas MD Anderson Cancer Center . (mdanderson.org)
  • The team observed that patients whose myeloma cells expressed low TJP1 levels were significantly less likely to achieve a response or benefit from bortezomib. (mdanderson.org)
  • This study allows us to identify promising future directions to overcome proteasome inhibitor resistance in patients with high signaling through EGFR/JAK1/STAT3 pathway by offering combination therapies such as bortezomib with either the EGFR inhibitor erlotinib, or a JAK1 inhibitor such as ruxolitinib," said Orlowski. (mdanderson.org)
  • Important questions that have not yet been resolved include the optimal dose and duration of thalidomide, whether clinical benefit depends on response to induction therapy and risk for relapse, and whether reported benefits are caused by cytoreduction or eradication of minimal residual disease, especially with bortezomib maintenance. (jnccn.org)
  • Ongoing randomized trials are evaluating lenalidomide and bortezomib maintenance therapies to better define the role of these drugs as maintenance in multiple myeloma. (jnccn.org)
  • Many of these adverse events have been documented only in the past 5 to 10 years, in conjunction with the introduction of a series of the newer therapies thalidomide, bortezomib, and lenalidomide. (jnccn.org)
  • [ 3 ] Any one of the combination regimens below, most of them based on bortezomib, may be used for induction therapy. (medscape.com)
  • BCMA, or B-cell maturation antigen, is a protein found on the surface of plasma cells that helps to regulate the growth and survival of B-cells, but is also found on myeloma cells in abnormally large amounts. (healthtree.org)
  • GPRC5D is another protein found on myeloma cells that bispecific antibodies can target. (healthtree.org)
  • What Treatments Can be Used Following a BCMA Relapse in Myeloma? (healthtree.org)
  • Some of the most dramatic advances in multiple myeloma treatment include BCMA-targeting treatments - CAR T and bispecific antibodies. (healthtree.org)
  • Gurbakhash Kaur, MD from UT Southwestern at the American Society of Hematology 2022 conference shows that patients who have received BCMA-specific therapy can respond to other BCMA-bispecific antibodies and CAR T therapy, even after relapse. (healthtree.org)
  • BCMA targeting bi-specific antibodies can help the patient's own immune system to target BCMA proteins in order to destroy myeloma cells. (healthtree.org)
  • One of the most promising BCMA-specific therapies is CAR-T cell therapy. (healthtree.org)
  • At the ASH 2022 conference, many researchers presented data addressing the concern of relapse after BCMA-specific therapy. (healthtree.org)
  • Data showed that patients who have received BCMA-specific therapy can go on to respond to other BCMA bispecific antibodies, such as belantamab-mafodotin (currently off the market but potentially coming back on next year). (healthtree.org)
  • You can read more about the specific research and potential therapies related to progression after BCMA-targeted CAR-T therapy here . (healthtree.org)
  • Approval for the BCMA CAR-T was recommended for fourth-line treatment for multiple myeloma. (ppf.eu)
  • Currently, CAR T-cell therapy for MM is at the first stage of clinical studies, and most studies have focused on CAR T cells targeting B cell maturation antigen (BCMA), but other antigens such as cluster of differentiation 138 (CD138, syndecan-1) are also being evaluated. (edu.pl)
  • Patients with multiple myeloma who relapse after treatment with B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy can be salvaged with multiple lines of therapy, a retrospective study suggested. (medpagetoday.com)
  • Patients with multiple myeloma who relapse after BCMA-directed CAR T have a limited prognosis but can be potentially treated with multiple lines of salvage therapy," they wrote. (medpagetoday.com)
  • This suggests that for eligible patients that progress after BCMA-directed CAR T, additional T-cell-engaging therapies contribute meaningfully to survival and that T-cell activation is feasible down the line," Parekh and team wrote. (medpagetoday.com)
  • From March 2017 to January 2022, 140 patients with multiple myeloma were treated with a BCMA-directed CAR T-cell therapy on a clinical trial at either the Mount Sinai Tisch Cancer Institute or Memorial Sloan Kettering Cancer Center in New York City. (medpagetoday.com)
  • Although BCMA CAR -T therapy induces certain complications in some patients , idiopathic thrombocytopenic purpura ( ITP ) has not been reported as one of them. (bvsalud.org)
  • Translational Candidate s15.BsAb.BCMA-CAR NK cells derived from CD34(+) umbilical cord blood hematopoietic stem cells Area of Impact patients with multiple myeloma Mechanism of Action s15.BsAb.BCMA-CAR NK cells are umbilical cord blood-derived CD34+ hematopoietic stem cells that are engineered to include two components of the BCMA-CAR and the anti-NKG2D-anti-GPRC5D BsAb. (ca.gov)
  • Area of Impact Translational candidate will enable treatment of patients with heterogeneous or BCMA- multiple myeloma and prevent cancer relapse due to antigen loss. (ca.gov)
  • According to Jonathan Keats, Ph.D . , Director of Bioinformatics at TGen, Scientific Director of the Judy and Bernard Briskin Center for Multiple Myeloma Research at City of Hope, and a co-author on the paper, the currently approved T cell therapies target either B cell maturation antigen (BCMA) or the GPRC5D protein on the surface of tumor cells. (tgen.org)
  • Previous research showed that some patients progressing on BCMA directed therapies had lost the target gene, but this study shows many patients lack a copy of the gene for one of these proteins (about 3% of patients for BCMA and about 15% for GPRC5D) when they are first diagnosed. (tgen.org)
  • While all prior approvals with CAR T have directed the engineered T-cells to CD19, a marker on the surface of malignancies derived from B-cells, this is the first approval of a B-cell maturation antigen (BCMA)-directed CAR T. Idecabtegene vicleucel or ide-cel (Abecma) is the first approval of a CAR T for multiple myeloma. (lls.org)
  • Ide-cel works by targeting a protein called BCMA that plays a key role in multiple myeloma. (lls.org)
  • In particular, Elrexfio is a BCMA-CD3-directed bispecific antibody immunotherapy that is delivered subcutaneously (beneath the skin) and aims to activate T-cells to kill myeloma cells. (curetoday.com)
  • This study also established Elrexfio as the first BCMA-directed therapy in the U.S. with once-every-other-week dosing for responding patients after 24 weeks of weekly therapy, which means less time at the clinic and potentially greater long-term treatment tolerability," according to the release. (curetoday.com)
  • Data from MagnetisMM-3 also included 63 patients who received at least four lines of therapy including a BCMA-directed therapy. (curetoday.com)
  • In individuals with multiple myeloma, acupuncture has been shown to improve nausea and vomiting, appetite, pain, and drowsiness. (healthline.com)
  • But because individuals with multiple myeloma may also have anemia, neutropenia, or other conditions that can increase these risks, it's important to get care from a trained expert to ensure they use safe techniques. (healthline.com)
  • 3 After initial therapy, it is common for individuals with multiple myeloma to become less responsive to therapy or eventually experience a relapse, when the cancer returns. (novartis.com)
  • Treatment options are expanding and providing better long-term survival for many people. (healthline.com)
  • Maintenance therapy aims to make this period last as long as possible, and it may improve survival rates for people with MM. (medicalnewstoday.com)
  • Among 79 patients who were given a total of 237 salvage treatments, median overall survival (OS) from the date of relapse post-CAR T-cell therapy was 17.9 months (95% CI 14.0 to not estimable [NE]), reported Samir Parekh, MD, of the Icahn School of Medicine at Mount Sinai in New York City, and colleagues. (medpagetoday.com)
  • The median progression-free survival (PFS) with the first attempted salvage therapy was 3.5 months. (medpagetoday.com)
  • We retrospectively analyzed clinical characteristics, response to treatment and survival of 282 patients with active newly-diagnosed multiple myeloma, comparing results between patients younger and older than 65 years. (scielo.br)
  • Outcome and survival of myeloma patients diagnosed 2008-2015. (scielo.br)
  • Most data regarding the impact of age on survival mainly come from clinical trials developed before the current therapy choices were in use. (scielo.br)
  • The aims of the present study were to describe clinical features at diagnosis, response to treatment and survival in 282 patients with active newly-diagnosed MM (NDMM) and compare outcomes between patients younger and older than 65 years. (scielo.br)
  • Further research will determine whether panobinostat affects overall survival and whether the tradeoff of clinical benefits and adverse events justify approval of the treatment for patients with relapsed multiple myeloma. (pharmacytimes.com)
  • While multiple myeloma care and outcomes have improved, the disease remains incurable and patients like the ones in the KarMMa study, whose cancer has progressed despite treatment with at least three previous therapies, face poor survival rates. (lls.org)
  • While the disease is considered incurable, and the relative five-year survival rate for patients diagnosed with multiple myeloma in the US is approximately 50%, the addition of multiple new FDA-approved therapies to treat the disease are likely to increase overall survival rates in the future. (lls.org)
  • Survival of multiple myeloma has almost doubled over the last decade, and the very positive outcomes from use of the three-drug combination will likely further improve outcomes," he says. (sciencedaily.com)
  • Nationwide, the median survival rate of patients with multiple myeloma is only about four years. (uamshealth.com)
  • But at our UAMS Myeloma Center, the survival rate is closer to eight or nine years, and many patients treated at our center are considered cured. (uamshealth.com)
  • Five-year survival rates at the Myeloma Center are greater than 65% - nearly twice the average of any other treatment facility. (uamshealth.com)
  • Progression-free survival for people who have received an HDT-ASCT combination therapy is around 3.5 years. (janssen.com)
  • That said, this overall survival is not a guarantee, and the toxicities of this combination of treatments can also impact a person's quality of life, and sometimes even limit life expectancy. (janssen.com)
  • If you have stage III multiple myeloma and you're unsure about what staging means or what your survival rate looks like, ask your doctor to explain it to you. (webmd.com)
  • A new immunomodulatory drug under review by the FDA was found to significantly increase progression-free and overall survival in persons with multiple myeloma, including older patients, according to research reported at the annual meeting of the American Society of Hematology, held December 8-11, 2012, in Atlanta, Georgia. (oncologynurseadvisor.com)
  • Several outcomes had not yet been reached at follow-up including overall survival (the time from treatment assignment when a patient with cancer is alive), duration of response and progression-free survival (the time during and after treatment when a patient with cancer lives without disease worsening), meaning that the outcome did not occur in more than half of patients in the study. (curetoday.com)
  • Impact of Antibiotic Exposure Before ICIs on Cancer Survival These findings highlight the importance of considering prior antibiotic use before initiating ICI therapy in cancer patients. (medscape.com)
  • New Medicines and De Novo Metastatic Cancer Survival Changes What impact have newly approved treatment options had on the survival of patients with de novo metastatic cancers? (medscape.com)
  • Thus, asymptomatic subjects did not benefit from early treatment, and delayed treatment did not affect treatment efficacy (ie, survival). (medscape.com)
  • Similarly, curcumin, a substance found in turmeric, has some evidence supporting its use against cancers like multiple myeloma. (healthline.com)
  • MGUS (monoclonal gammopathy of uncertain significance) and smoldering myeloma cause no symptoms but refer to the development of abnormal cells that can eventually lead to multiple myeloma or related cancers. (dukehealth.org)
  • As part of our mission to eliminate cancer, MD Anderson researchers conduct hundreds of clinical trials to test new treatments for both common and rare cancers. (mdanderson.org)
  • Early Mortality in ICI-Treated Cancers in Routine Practice A better understanding of the predictors of early mortality among cancer patients treated with ICIs could help guide treatment selection. (medscape.com)
  • The Emerging Role for CAR T Cells in Solid Tumor Oncology Learn more about the exciting potential role of CAR T cells in the targeted treatment of solid tumor cancers. (medscape.com)
  • With no curative therapies, treatment plans are based on: age/general health, results of laboratory/genomic tests, symptoms/disease complications and prior treatment. (novartis.com)
  • Venous thromboembolism (VTE), osteonecrosis of the jaw, renal failure, and anemia are all common complications of multiple myeloma therapy. (jnccn.org)
  • Some people don't have any complications from their multiple myeloma. (webmd.com)
  • MM can range from asymptomatic to severely symptomatic with complications requiring emergent treatment. (medscape.com)
  • Overall, the care of patients with MM is complex and should focus on treatment of the disease process and any associated complications. (medscape.com)
  • Multiple myeloma (MM) is a debilitating neoplasm of terminally differentiated plasma B cells that resulted in over 13,000 deaths in 2017 alone. (snmjournals.org)
  • Today marks the seventh approval of CAR T therapy since the first approval in 2017. (lls.org)
  • Several myeloma abstracts were presented at the American Society of Clinical Oncology (ASCO) 2017 annual meeting that I initially reviewed on Medscape's ASCO 2017 Live Blog . (medscape.com)
  • Cite this: Joseph Mikhael: ASCO 2017 Takeaways in Myeloma - Medscape - Jun 26, 2017. (medscape.com)
  • The 2009 International Myeloma Workshop concluded that detection of any cytogenic abnormality suggests higher-risk disease, including chromosomal 13 or 13q deletion, t(4;14), and del17p and fluorescence in situ hybridization detection of t(4;14), t(14;16), and del17p. (medscape.com)
  • These data represent the first assessment of daratumumab in combination with a next generation proteasome inhibitor (PI) and an immunomodulatory agent earlier in the treatment paradigm for multiple myeloma. (jnj.com)
  • Currently, combinations of proteasome inhibitors (PI) and/or immunomodulatory drugs (IMiD) +/- the monoclonal antibody Daratumumab are used for first-line treatment, even if head-to-head comparisons are lacking. (cun.es)
  • 8 Patients who relapse after treatment with standard therapies, including protease inhibitors and immunomodulatory agents, have poor prognoses and few treatment options available. (pharmiweb.com)
  • These four lines of therapy include an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 monoclonal antibody, according to a press release from Pfizer, the manufacturer of the therapy. (curetoday.com)
  • Despite the significant progress of modern anticancer therapies, multiple myeloma (MM) is still incurable for the majority of patients. (edu.pl)
  • Myeloma remains incurable, but with these approaches we hope that it will become a chronic disease in the not-so-distant future. (medscape.com)
  • Based on its oral administration and the reduced incidence of infection and cytopenia, cyclophosphamide-thalidomide-dexa-methasone may be considered an effective induction therapy option for patients with newly diagnosed multiple myeloma. (haematologica.org)
  • The treatment scenario for newly-diagnosed transplant-ineligible multiple myeloma patients (NEMM) is quickly evolving. (cun.es)
  • Review of 1027 patients with newly diagnosed multiple myeloma. (scielo.br)
  • The 'gold standard": What is the current recommended treatment for newly diasnosed multiple myeloma? (janssen.com)
  • High-dose melphalan followed by ASCT, as well as maintenance with lenalidomide, remain standard treatment for transplant-eligible patients with newly diagnosed multiple myeloma. (medpagetoday.com)
  • A 2022 study found that increased incidences of multiple myeloma were associated with "higher human development index and gross domestic products, prevalence of physical inactivity, overweight, obesity, and diabetes. (healthline.com)
  • Treatment of Metastatic Uveal Melanoma in 2022 Recent developments in our understanding of metastatic uveal melanoma and treatment advancements have improved the prognosis of these patients. (medscape.com)
  • Following almost three decades of development, chimeric antigen receptor (CAR) T-cell therapy now has the opportunity to revolutionize the treatment landscape and meet the unmet clinical need. (edu.pl)
  • Chimeric antigen receptor (CAR) T-cell therapy is designed to enhance the body's immune system to effectively kill malignant cells. (ajmc.com)
  • The deal comes a week after the company reported its preliminary sales of multiple myeloma CAR T therapy Carvykti ciltacabtagene autoleucel, which brought in $24 million in 2Q22. (ppf.eu)
  • The goal of this research study is to test if ciltacabtagene autoleucel (cilta-cel) is safe and effective in treating participants with high-risk, smoldering myeloma. (dana-farber.org)
  • SOMERSET, N.J.--(BUSINESS WIRE)-- $LEGN --Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare (MHLW) for ciltacabtagene autoleucel (cilta-cel) by its collaboration partner, Janssen Pharmaceutical K.K. (Janssen). (pharmiweb.com)
  • Carfilzomib is a proteasome inhibitor approved for use in 2012 by the U.S. Food and Drug Administration (FDA) for patients with advanced, end-stage multiple myeloma. (sciencedaily.com)
  • TJP1 has not previously been known to play any role as a mediator of proteasome inhibitor sensitivity in multiple myeloma. (mdanderson.org)
  • As a community, we have gone from the development of a first-in-class proteasome inhibitor treatment some twenty years ago, to now exploring the ground-breaking reaches of personalised medicine through CAR-T therapy and beyond. (janssen.com)
  • Many breakthroughs in therapies to treat myeloma have been accomplished at our center. (uamshealth.com)
  • The findings could help clinicians and patients choose from among a variety of T cell therapies for multiple myeloma to find treatments that best match a patient's available tumor targets. (tgen.org)
  • Some complementary therapies don't have strong evidence indicating they improve outcomes. (healthline.com)
  • Daratumumab appeared to improve poor outcomes associated with high risk cytogenetics, and these data support its consistent clinical benefit in combination with two of the most widely used treatment classes. (jnj.com)
  • The application of risk-based therapy and the potential of the new agents to abrogate the influence of adverse prognostic features may improve outcomes in these patients. (jnccn.org)
  • Preventive measures, such as VTE prophylaxis and appropriate dental hygiene, as well as patient education, dose adjustments, limited duration of drug treatment, and consideration of therapies that are associated with less burdensome adverse-event profiles, can contribute to substantially improved outcomes and quality of life. (jnccn.org)
  • Surgical Lymphedema Treatment A new review looks at the surgical options for lymphedema and recommends a standardized protocol for optimizing treatment outcomes. (medscape.com)
  • It aims to improve outcomes by ensuring the most effective investigations and treatment. (bvsalud.org)
  • Presentations are available online starting Friday, June 12, 2020, and include positive results from TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO ™ (ixazomib) as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma who had not been treated with stem cell transplantation. (takeda.com)
  • Among the newest types of treatments for multiple myeloma are T cell immunotherapies that target specific tumor proteins. (tgen.org)
  • Although the therapies have shown promise, patients can relapse if mutated versions of the proteins-which can't be targeted by the T cells - become more prevalent in a tumor. (tgen.org)
  • This study has uncovered a variety of other ways that these two proteins can be mutated, including ways that help the tumor "escape" targeting by the therapy," said Keats. (tgen.org)
  • These special proteins -- called bispecific antibodies -- help your immune system recognize the multiple myeloma cells in your body and destroy them. (dukehealth.org)
  • The drug specifically targets regulation of the proteins that fuel growth of multiple myeloma. (sciencedaily.com)
  • Moreover, they demonstrated a previously unknown role for EGFR signaling in myeloma, and for STAT3 in controlling the level of proteasomes in cells, and therefore the cell's ability to break down proteins. (mdanderson.org)
  • The 79 patients included in this analysis had a median age of 60 years at the time of progression after CAR T-cell therapy, and 60% were men. (medpagetoday.com)
  • Characteristics of the disease at diagnosis, first-line treatment and response, date of progression or death and cause of mortality were detailed. (scielo.br)
  • Aetna considers continuation of carfilzomib (Kyprolis) therapy medically necessary for members requesting reauthorization for an indication listed in Section I when there is no evidence of unacceptable toxicity or disease progression while on the current regimen. (aetna.com)
  • Interim analysis of the ASPIRE clinical trial, which enrolled 792 patients with relapsed multiple myeloma from 20 countries, found an "unprecedented" prolongation of the time patients were free of disease progression, says the study's lead investigator, Keith Stewart, M.B., Ch.B, a Mayo Clinic oncologist in Arizona. (sciencedaily.com)
  • Throughout the multiple myeloma journey, a treatment team works with the patient to introduce different therapy combinations to address treatment resistance and/or disease progression. (novartis.com)
  • Kyprolis did dramatically slow progression of my myeloma over the past year. (drugs.com)
  • and had experienced disease progression within 60 days of their last treatment. (oncologynurseadvisor.com)
  • At progression, patients receiving pomalidomide monotherapy could be switched to the combination therapy at the investigator's discretion. (oncologynurseadvisor.com)
  • Consolidation reduced the risk of progression or death in most predefined subgroups, including revised International Staging System (ISS) stage I to III disease, standard-risk cytogenetics, and prior treatment. (medpagetoday.com)
  • A systematic review by He et al demonstrated a reduction in vertebral compressions and time to progression with early systemic treatment for asymptomatic patients, but this study also revealed an increase in acute leukemia in the early treatment group. (medscape.com)
  • When myeloma cells develop into a single collection of cells, typically in the bone, it is called a solitary plasmacytoma. (dukehealth.org)
  • Poseida Therapeutics is testing the safety of a gene modified cell therapy to treat multiple myeloma, the abnormal growth of malignant plasma cells of the immune system. (ca.gov)
  • In 2020, an estimated 170,405 people were living with myeloma in the United States. (healthline.com)
  • In addition to a Breakthrough Therapy Designation (BTD) granted in the U.S. in December 2019, cilta-cel received a Priority Medicines (PRiME) designation from the European Commission in April 2019, and a BTD in China in August 2020. (pharmiweb.com)
  • Subscribe to the weekly 'HealthTree Community for Multiple Myeloma Newsletter' for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts. (healthtree.org)
  • Clinical trials in the early 2010s using second generation CARs targeting CD19, a protein expressed by normal B cells as well as B-cell leukemias and lymphomas, by investigators at the NCI, University of Pennsylvania, and Memorial Sloan Kettering Cancer Center demonstrated the clinical efficacy of CAR T cell therapies and resulted in complete remissions in many heavily pre-treated patients. (wikipedia.org)
  • In the meantime, I would suggest that this is not ready for prime time and should be explored for myeloma only in clinical trials. (medscape.com)
  • Cartography is expanding the world of tumor antigen targets for CAR T cells and other new modality therapies with a platform that can pick up on targets missed by conventional screening methods. (ppf.eu)
  • Effect of Targeted RA Therapies on Inflammation and Anemia In what ways do various targeted DMARDs impact systemic inflammation and anemia in patients with rheumatoid arthritis? (medscape.com)
  • In general, the first decision made in the management of patients with myeloma who require systemic therapy is whether stem cell transplantation is part of the strategy. (medscape.com)
  • ABSTRACT Multiple myeloma (MM) is a systemic malignancy of pathologic plasma cells that is treat able with chemotherapeutic agents and irradiation, but rarely curable. (who.int)
  • Doctors grade multiple myeloma cases as high, intermediate, or standard risk, based on genes in the tumors. (webmd.com)
  • Jingda did not more precisely disclose the amount of money raised, but said it would be used to advance its first CAR NK cell therapy into the clinic to treat hematological tumors and undertake preclinical research of assets targeting solid tumors. (ppf.eu)
  • Multiple myeloma refers to the presence of several myeloma tumors. (dukehealth.org)
  • Innovations in immunotherapy have led to the development of multiple immune-targeted therapies to manage malignancy. (ajmc.com)
  • Our initial investment in CAR T in the 1990's, when CAR T, and indeed immunotherapy to treat cancer was in its infancy, has turned into a game-changing therapeutic giving new hope to patients with limited treatment options and often very poor prognoses. (lls.org)
  • Complementary therapies help make sure those symptoms and side effects are addressed so that you have the highest quality of life possible while also managing cancer. (healthline.com)
  • Massage therapy is frequently used as a complementary therapy to reduce stress, pain, anxiety, and other symptoms. (healthline.com)
  • There's no cure, but treatments can slow its spread and sometimes make symptoms go away. (webmd.com)
  • If you don't have symptoms, your doctor may choose to watch you closely rather than start treatment right away. (webmd.com)
  • If you have symptoms, your doctor will work with you to come up with a treatment plan. (webmd.com)
  • For example, if you are experiencing smoldering myeloma or MGUS, which typically do not produce symptoms, we may recommend active surveillance of your myeloma. (dukehealth.org)
  • Young, healthy people with symptoms may tolerate more intensive therapies, while older or frail people may benefit from gentler treatment options. (dukehealth.org)
  • Often recommended if you have smoldering myeloma, or MGUS, which do not cause symptoms. (dukehealth.org)
  • We monitor you regularly and start treatment if symptoms appear or changes in your condition occur. (dukehealth.org)
  • Some people have a form of multiple myeloma that grows slowly (smoldering myeloma), which takes years to cause symptoms. (medlineplus.gov)
  • 6 , 7 While some patients with multiple myeloma have no symptoms at all, most patients are diagnosed by symptoms that can include bone problems, low blood counts, calcium elevation, kidney problems or infections. (pharmiweb.com)
  • The process for administering CAR T-cell therapy is complex, with multiple steps including CAR T-cell manufacturing, lymphodepleting chemotherapy, cellular therapy infusion, and management of short-term and long-term toxicities. (ajmc.com)
  • Chemotherapy maintenance offers no benefit after conventional or high-dose treatment. (jnccn.org)
  • 1 CAR T-cell therapy pivotal trials demonstrated unprecedented overall response rates (ORRs) and complete responses (CRs) that led to the FDA approval of 5 CAR T-cell products: tisagenlecleucel (tisa-cel), axicabtagene ciloleucel (axi-cel), lisocabtagene maraleucel (liso-cel), brexucabtagene autoleucel (brexu-cel), and idecabtagene vicleucel (ide-cel). (ajmc.com)
  • Are you (or will you be) treating your multiple myeloma patients with Vorinostat or Carfilzomib? (cancertherapyadvisor.com)
  • Precertification of carfilzomib (Kyprolis), for multiple myeloma only, is required of all Aetna participating providers and members in applicable plan designs. (aetna.com)
  • For precertification of carfilzomib (Kyprolis), for multiple myeloma only, call (866) 752-7021 (Commercial), or fax (888) 267-3277. (aetna.com)
  • In the treatment of multiple myeloma, the addition of carfilzomib to a currently accepted two-drug combination produced significantly better results than using the two drugs alone, according to a worldwide research team. (sciencedaily.com)
  • The number of patients who responded to treatment was also significantly improved by adding carfilzomib to standard treatment -- 87.4 percent versus 66.9 percent -- and more than three times more patients had no detectable disease after the three-drug treatment (31.8 percent versus 9.3 percent). (sciencedaily.com)
  • Carfilzomib in frontline myeloma is becoming more prolific. (medscape.com)
  • For a better explanation on how bispecific antibodies work to kill myeloma, check out this video on HealthTree University . (healthtree.org)
  • 3 Although treatment may result in remission, most patients experience relapse. (pharmiweb.com)
  • Most multiple myeloma patients will experience relapse or resistance of their disease to treatment, often facing increased symptom burden and lowering their chance of surviving longer with each attempted line of therapy," MagnetisMM clinical trial investigator Dr. Ajay Nooka, director of the multiple myeloma program at Winship Cancer Institute of Emory University, said in the release. (curetoday.com)
  • Multiple myeloma is most common among older patients who also face the worst prognosis and often have limited treatment option. (lls.org)
  • Recently, genetic analysis has provided predictable prognosis across different types of treatment. (jnccn.org)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • On any given day, there are more than 200 myeloma patients staying in Little Rock for diagnosis and treatment. (uamshealth.com)
  • Because multiple myeloma starts when healthy plasma cells become abnormal and grow out of control, when you have stage III, your body may have a large number of these cells. (webmd.com)